Back to top
more

Hyperfine (HYPR)

(Delayed Data from NSDQ)

$1.16 USD

1.16
128,943

+0.01 (0.87%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $1.16 0.00 (0.00%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software

by Zacks Equity Research

Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop

by Zacks Equity Research

Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

by Zacks Equity Research

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.

Sanghamitra Saha headshot

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).

Hyperfine, Inc. (HYPR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 8.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Hyperfine, Inc. (HYPR) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Hyperfine (HYPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down -19% in 4 Weeks, Here's Why Hyperfine (HYPR) Looks Ripe for a Turnaround

by Zacks Equity Research

Hyperfine (HYPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Hyperfine, Inc. (HYPR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of 11.76% and 26.61%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 37.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 26.92% and 2.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod

by Zacks Equity Research

Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.

Down -21.28% in 4 Weeks, Here's Why Hyperfine, Inc. (HYPR) Looks Ripe for a Turnaround

by Zacks Equity Research

Hyperfine, Inc. (HYPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -15.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Hyperfine, Inc. (HYPR)

by Zacks Equity Research

Hyperfine, Inc. (HYPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Hyperfine, Inc. (HYPR) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Hyperfine, Inc. (HYPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Hyperfine, Inc. (HYPR) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Hyperfine, Inc. (HYPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -57.33% and 26.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -61.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 16.13% and 2.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Silk Road Medical (SILK) delivered earnings and revenue surprises of 10.26% and 4.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Hyperfine (HYPR) ACTION PMR Study Targets Better Stroke Care

by Zacks Equity Research

Hyperfine's (HYPR) ACTION PMR study focuses on utilizing point-of-care brain imaging to identify strokes and salvageable brain tissue.

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 33.33% and 2.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 88.89% and 8.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -12.50% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Microsoft, Novo Nordisk, General Mills in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day.